2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1149

Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 459

Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
Abstract Number: 1640

Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Abstract Number: 259

Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results
Abstract Number: 1304

Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Abstract Number: 653

Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare
Abstract Number: 2205

Longitudinal Evaluation of the Performance of Different Classification Criteria in Patients with Primary Sjögren’s Syndrome
Abstract Number: 86

Longitudinal Hypertension Diagnosis and Control Among a Primary Care Medically Homed Population with Rheumatoid Arthritis
Abstract Number: 1935

Longitudinal Peripheral Blood Lymphocyte Subsets Correlate with Decreased Disease Activity in Juvenile Dermatomyositis
Abstract Number: 2679

Loss of Caspase 8 in Dendritic Cells Induces a Systemic Lupus Erythematosus-Like Disease That Is Independent of the Necroptosome
Abstract Number: 420

Loss-of-Co-Homozygosity Mapping and Exome Sequencing of a Syrian Pedigree Identified the Candidate Causal Mutation Associated with Rheumatoid Arthritis
Abstract Number: 1981

Low Body Mass Index, Medication Use and Social Factors Such As Smoking but Not Secondary Medical Disorders or Older Age May Be More Prevalent in Males with Low Bone Mineral Density
Abstract Number: 923

Low Bone Mineral Density and Higher Parathyroid Hormone Levels As Independent Factors to All-Cause Mortality in Community-Dwelling Older Adults: the São Paulo Ageing & Health Study (SPAH)
Abstract Number: 1511

Low Circulating Endothelial Progenitor Cell Levels and High VEGF Serum Levels Are Associated with the Late Nailfold Capillaroscopic Pattern in Systemic Sclerosis
Abstract Number: 2515

Low Density Lipoprotein Receptor Deficiency Results in Osteophyte Formation During Experimental Osteoarthritis Which Is Enhanced Under High Cholesterol Conditions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].